Functional divergence between 2 chemokines is conferred by single amino acid change

Blood

Volumn 116, Issue 22, 2010, Pages 4703-4711

  Dubrac, Alexandre ^a,b   Quemener, Cathy ^a   Lacazette, Eric ^b   Lopez, Fréderic ^b   Zanibellato, Catherine ^b   Wu, Wen Guey ^c   Bikfalvi, Andréas ^a   Prats, Hervé ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCL4; CHEMOKINE RECEPTOR CXCL4L1; CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HISTIDINE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; HUMAN; HUMAN CELL; IC 50; INFLAMMATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS; TISSUE REPAIR; WESTERN BLOTTING;

EID: 78649467573     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-274852     Document Type: Article

References (38)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932-936.
2. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci. 2009;14:540-551.
3. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007;25:787-820.
4. Hacker U, Nybakken K, Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol. 2005;6(7):530-541. (Pubitemid 40943044)
5. Sasisekharan R, Venkataraman G. Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol. 2000;4(6):626-631.
6. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol. 2008;28(11):1928-1936.
7. Yamaguchi K, Ogawa K, Katsube T, et al. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res. 2005;25(2A):847-851.
8. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006;42(6):768-778.
9. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood. 1998;91(9):3289-3299. (Pubitemid 28193879)
10. Jouan V, Canron X, Alemany M, et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood. 1999;94(3):984-993.
11. Hagedorn M, Zilberberg L, Lozano RM, et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 2001;15(3):550-552.
12. Ragona L, Tomaselli S, Quemener C, Zetta L, Bikfalvi A. New insights into the molecular interaction of the C-terminal sequence of CXCL4 with fibroblast growth factor-2. Biochem Biophys Res Commun. 2009;382(1):26-29.
13. Bello L, Lucini V, Costa F, et al. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clin Cancer Res. 2004;10(13):4527-4537.
14. Aidoudi S, Bujakowska K, Kieffer N, Bikfalvi A. The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS ONE. 2008;3(7):e2657.
15. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003;197(11):1537-1549.
16. Struyf S, Burdick MD, Peeters E, et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007;67(12):5940-5948.
17. Lasagni L, Grepin R, Mazzinghi B, et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood. 2007;109(10):4127-4134.
18. Bossard C, Van den Berghe L, Laurell H, et al. Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide. Cancer Res. 2004;64(20):7507-7512.
19. Bornes S, Prado-Lourenco L, Bastide A, et al. Translational induction of VEGF internal ribosome entry site elements during the early response to ischemic stress. Circ Res. 2007;100(3):305-308.
20. Maione TE, Gray GS, Hunt AJ, Sharpe RJ. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. 1991;51(8):2077-2083.
21. Rao AK, Niewiarowski S, James P, et al. Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood. 1983;61(6):1208-1214.
22. Rucinski B, Niewiarowski S, Strzyzewski M, Holt JC, Mayo KH. Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. Thromb Haemost. 1990;63(3):493-498.
23. Mixon TA, Dehmer GJ. Recombinant platelet factor 4 for heparin neutralization. Semin Thromb Hemost. 2004;30(3):369-377.
24. Cochran S, Li CP, Ferro V. A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconj J. 2009;26(5):577-587.
25. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res. 2004;95(9):855-857.
26. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation. 1995;91(8):2188-2194.
27. Kaiser P, Harenberg J, Walenga JM, et al. Effects of a heparin-binding protein on blood coagulation and platelet function. Semin Thromb Hemost. 2001;27(5):495-502.
28. Romagnani P, Maggi L, Mazzinghi B, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol. 2005;116(6):1372-1379.
29. Cheng SH, Ng MH, Lau KM, et al. 4q loss is potentially an important genetic event in MM tumori-genesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4. Blood. 2007;109(5):2089-2099.
30. Dager WE, White RH. Pharmacotherapy of heparin-induced thrombocytopenia. Expert Opin Pharmacother. 2003;4(6):919-940.
31. Eisman R, Surrey S, Ramachandran B, Schwartz E, Poncz M. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood. 1990;76(2):336-344.
32. Xiao Z, Visentin GP, Dayananda KM, Neelamegham S. Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood. 2008;112(4):1091-1100.
33. Baltus T, von Hundelshausen P, Mause SF, Buhre W, Rossaint R, Weber C. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol. 2005;78(2):435-441.
34. Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood. 2003;101(12):4687-4694.
35. Nassar T, Sachais BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem. 2003;278(8):6187-6193.
36. Vandercappellen J, Noppen S, Verbeke H, et al. Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. J Leukoc Biol. 2007;82(6):1519-1530.
37. Cervi D, Yip TT, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2008;111(3):1201-1207.
38. Maier M, Geiger EV, Henrich D, et al. Platelet factor 4 is highly upregulated in dendritic cells after severe trauma. Mol Med. 2009;15(11-12):384-391.